Compare AP & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AP | ATNM |
|---|---|---|
| Founded | 1929 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 50.2M |
| IPO Year | N/A | N/A |
| Metric | AP | ATNM |
|---|---|---|
| Price | $2.74 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 193.2K | ★ 223.5K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $426,314,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.20 | ★ 11.11 |
| 52 Week Low | $1.75 | $1.03 |
| 52 Week High | $3.99 | $2.41 |
| Indicator | AP | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 47.64 |
| Support Level | $2.46 | $1.25 |
| Resistance Level | $2.99 | $1.48 |
| Average True Range (ATR) | 0.30 | 0.10 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 77.83 | 35.85 |
Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.